Sandoz Group AG (LTS:0SAN) 3-Year Share Buyback Ratio : 0.00% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG 3-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Sandoz Group AG's current 3-Year Share Buyback Ratio was 0.00%.

The historical rank and industry rank for Sandoz Group AG's 3-Year Share Buyback Ratio or its related term are showing as below:

During the past 3 years, Sandoz Group AG's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was 0.00%. And the median was 0.00%.

LTS:0SAN's 3-Year Share Buyback Ratio is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: -2.9
* Ranked among companies with meaningful 3-Year Share Buyback Ratio only.

Competitive Comparison of Sandoz Group AG's 3-Year Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's 3-Year Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's 3-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Sandoz Group AG 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Sandoz Group AG (LTS:0SAN) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Sandoz Group AG 3-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's 3-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (LTS:0SAN) » Definitions » 3-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZNY:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Centralbahnstrasse 4, Basel, CHE, 4051

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines